Biohaven (BHVN)

• Market cap: $1.63B
• 1 day: -5.26%
• 5 days: -2.61%
• 1 month: 11.23%
• 3 months: 4.75%
• 6 months: 13.09%
• Year to date: -0.37%
• 1 year: -33.33%
• 5 years: 51.26%
• 10 years: 51.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Employees: 274